The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
An open-label, phase Ib trial of the SIRPa inhibitor BI 765063 in combination with the PD-1 inhibitor ezabenlimab and cetuximab in patients (pts) with head and neck squamous cell carcinoma.
 
Katerin Rojas
No Relationships to Disclose
 
Iurie Bulat
No Relationships to Disclose
 
Napa Parinyanitikul
Honoraria - AstraZeneca; Eisai; MSD; Novartis; Pfizer; Roche
 
Emilio Murillo-Ramirez
No Relationships to Disclose
 
Tudor-Eliade Ciuleanu
Consulting or Advisory Role - A&D Pharma; Accord Healthcare; Amgen; Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Janssen; Lilly; MagnaPharm; Merck Serono; Merck Sharp & Dohme; Novartis; Pfizer; Roche; Sanofi; SERVIER; Takeda
Travel, Accommodations, Expenses - A&D Pharma; Amgen; Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Ipsen; Janssen; Lilly; Merck; MSD; Novartis; Pfizer; Roche/Genentech; Sanofi; Servier
 
François Ghiringhelli
Honoraria - roche
Research Funding - AstraZeneca/MedImmune (Inst)
Travel, Accommodations, Expenses - Amgen; Amgen; Amgen; Roche/Genentech; Roche/Genentech
 
Marc Oliva
Honoraria - Bristol-Myers Squibb/Pfizer; Bristol-Myers Squibb/Pfizer; Merck; MSD Oncology; Transgene
Consulting or Advisory Role - Merck KGaA; MSD Oncology; MSD Oncology; Obatica
Research Funding - ALX Oncology (Inst); Bayer (Inst); BeiGene (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); GlaxoSmithKline (Inst); ISA Pharmaceuticals (Inst); Merck; MSD Oncology (Inst); Roche (Inst); Seagen (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - BeiGene; Boehringer Ingelheim; Bristol-Myers Squibb/Pfizer; Merck; MSD Oncology
Other Relationship - Merck; MSD Oncology
 
Laurentia Gales
No Relationships to Disclose
 
Kevin Harrington
Honoraria - Abbvie (Inst); ALX Oncology (Inst); AstraZeneca (Inst); BeiGene (Inst); Bicara Therapeutics (Inst); BMS (Inst); Boehringer Ingelheim (Inst); Exelixis (Inst); Flamingo Pharma (Inst); GlaxoSmithKline (Inst); Johnson and Johnson (Inst); Merck Serono (Inst); Merus (Inst); MSD (Inst); Nanobiotix (Inst); PDS Biotechnology (Inst); PsiVac Ltd (Inst); Replimune (Inst); Scenic Biotech
Consulting or Advisory Role - AstraZeneca (Inst); BMS (Inst); Boehringer Ingelheim (Inst); Merck Serono (Inst); MSD (Inst); Nanobiotix (Inst); Replimune (Inst)
Speakers' Bureau - BMS (Inst); Merck Serono (Inst); MSD (Inst)
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Replimune (Inst)
 
Slawomir Mandziuk
No Relationships to Disclose
 
Santiago Cabezas-Camarero
Honoraria - Bristol-Myers Squibb; Johnson & Johnson IM; Merck KGaA; MSD; Novocure
Consulting or Advisory Role - Bristol-Myers Squibb; Merck KGaA
Research Funding - Merck KGaA (Inst)
Expert Testimony - Merck KGaA
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Johnson & Johnson IM; Merck KGaA; MSD
 
Lena Herich
Employment - Staburo GmbH working for Boehringer Ingelheim
 
Milena Tosiek
Employment - Boehringer Ingelheim
 
Gunther Kretschmar
Employment - Boehringer Ingelheim
 
Douglas Adkins
Consulting or Advisory Role - Adlai Nortye; Boehringer Ingelheim; CUE Biopharma; Exelixis; Genmab/Seattle Genetics; Immunitas; InhibRx; Kura Oncology; Merck; Merck KGaA; Merus; NATCO Pharma; Purple Biotech; Regeneron; Sanofi; Seagen; TargImmune Therapeutics
Research Funding - Adlai Nortye (Inst); Alentis Therapeutics (Inst); AstraZeneca (Inst); AVEO (Inst); BeiGene (Inst); BioAtla (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Calliditas Therapeutics (Inst); Celgene (Inst); Cofactor Genomics (Inst); Coherus Biosciences (Inst); CUE Biopharma (Inst); Daiichi Sankyo Europe GmbH (Inst); Debiopharm Group (Inst); Epizyme (Inst); Erasca, Inc (Inst); Exelixis (Inst); Genmab (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Hookipa Biotech (Inst); Immutep (Inst); InhibRx (Inst); ISA Pharmaceuticals (Inst); Johnson & Johnson/Janssen (Inst); Kura Oncology (Inst); Lilly (Inst); Merck (Inst); Merus (Inst); NATCO Pharma (Inst); Novartis (Inst); Pfizer (Inst); Rgenta (Inst); Roche (Inst); Seagen (Inst); Takeda (Inst); Tempus (Inst); Tizona Therapeutics, Inc. (Inst); Vaccinex (Inst); Xilio Therapeutics (Inst)
Travel, Accommodations, Expenses - NATCO Pharma (Inst)